Skip to content

For Research & Educational Discussion Only. Not Medical Advice

BaselineForum

Sermorelin

Growth hormone-releasing hormone (GHRH) analog

Also known as GHRH(1-29), Geref, GRF 1-29

The shortest active GHRH fragment. Once approved, withdrawn commercially rather than for safety, and now mostly encountered as a compounded preparation.

What doses have been studied? What each trial gave, with the population it was given to.

Guide updated Oct 22, 2026Literature checked Oct 21, 20261 curated study26 literature recordsBaseline editorial

Overview

In shortThe shortest piece of growth hormone-releasing hormone that still works. It was approved for growth hormone deficiency in children and later discontinued, and that gets misrepresented in both directions. It was pulled for commercial reasons, not safety. That is not an endorsement either: a product that did not sell in its approved use tells you nothing about healthy adults.

Sermorelin is the first 29 amino acids of growth hormone-releasing hormone, the shortest fragment retaining full activity. It was approved for pediatric growth hormone deficiency, both diagnostically and therapeutically, and later discontinued.

The discontinuation is worth being precise about, because it gets misrepresented in both directions. It was a commercial decision, not a safety withdrawal. That is not an endorsement either: a product that was not commercially viable in its approved indication tells you nothing about whether it does anything useful in healthy adults, which is how it is mostly discussed now.

Mechanism

In shortIt tells the pituitary to make and release your own growth hormone, with the body's normal feedback left intact. It clears in minutes rather than hours, so it amplifies the pulses you already have rather than raising a constant level. That is a genuinely different pharmacology from the long-acting versions, and it is the same distinction that matters for CJC-1295.

Binds the GHRH receptor on pituitary somatotrophs, stimulating synthesis and pulsatile release of endogenous growth hormone, with pituitary negative feedback intact.

Its half-life is short, minutes rather than hours, so it amplifies existing GH pulses rather than raising a baseline. That is a meaningfully different pharmacology from long-acting GHRH analogs, and the distinction is the same one that matters for CJC-1295 with and without DAC.

Evidence

In shortEarly, and largely historical. Its approved use was in children with growth hormone deficiency, where it supported growth in those who responded. For body composition, sleep, recovery and aging in healthy adults there is no properly sized evidence. It raises growth hormone, therefore it does what growth hormone does, is the untested step.

Early clinical, and largely historical. Its approved use was in pediatric growth hormone deficiency, where it raised GH and IGF-1 and supported growth in responsive children.

For the uses that dominate current discussion, body composition, sleep, recovery and aging in healthy adults, there is no adequately powered controlled evidence. The reasoning is again mechanistic: it raises GH, therefore it should do the things GH is associated with. That step is the one that has to be tested and has not been.

Safety

In shortHistorical use in children was generally well tolerated, with injection site reactions, flushing and headache reported. Long-term use in healthy adults has never been characterized. The concerns follow from keeping growth hormone raised: insulin resistance, fluid retention, joint pain, and cell-growth implications. Compounded versions are not made to the standard of the withdrawn approved product.

Historical clinical use in children was generally well tolerated, with injection site reactions, flushing and headache reported.

Chronic use in healthy adults is uncharacterised. The mechanistic concerns are those of sustained GH and IGF-1 elevation: insulin resistance, fluid retention, arthralgia, and the mitogenic implications of chronic IGF-1 elevation.

Compounded preparations are not manufactured to the standard of the withdrawn approved product, and their identity and potency are unverified.

Regulatory status

In shortApproval withdrawn after the product was discontinued commercially. Now supplied mainly through compounding pharmacies in some countries, with a legal status that has moved repeatedly and differs sharply between them. Banned in sport.

Approval withdrawn after commercial discontinuation. Now supplied mainly through compounding pharmacies in some jurisdictions, with a legal status that has moved repeatedly and differs sharply by country. Prohibited in sport under WADA's S2 category.

The literature

1 study indexed. Findings and limitations get equal weight, on purpose.

Always check the primary source

Members area

The Sermorelin literature needs an account

Everything above is free to read. What an account opens is the evidence underneath it: 1 study with their limitations, and the regimen each trial actually reported.

  • Every study, with what it found and what it cannot show
  • The limitations, given the same weight as the findings
  • The dose each named trial administered, where recorded
Create a free accountI already have one

Free to create. A membership is separate, and you can decide about that later.

Reading is free, an account is not the same as paying. 80 compound guides, every study with its limitations written underneath, and the regimens those trials actually used. A free account opens all of it. A membership is a separate decision, and it opens the forum. What membership costs.

The wider literature

26 indexed papers and 0 registered trials mentioning Sermorelin, straight from PubMed and ClinicalTrials.gov. These have not been read by us. Unlike the studies above, they carry no findings and no limitations written by anyone here, because writing either would mean claiming a reading nobody has done. They are a starting point for yours.

Papers (26)

  1. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

    Rahman OF, et al.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews2026PMID 41490200

    journal articlereview

  2. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.

    Uçaktürk E, et al.Journal of pharmaceutical and biomedical analysis2026PMID 41138283

    journal article

  3. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

    Mendias CL, et al.Sports medicine (Auckland, N.Z.)2026PMID 41966639

    journal articlereview

  4. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

    Coutinho LFD, et al.The Journal of sports medicine and physical fitness2026PMID 41880199

    journal articlereview

  5. Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells.

    Gesmundo I, et al.International journal of molecular sciences2025PMID 40244089

    journal article

  6. Growth hormone - releasing hormone antagonists induce autophagy in cancer cells.

    Sigdel M, et al.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society2025PMID 41075421

    journal article

  7. A novel approach for the treatment of AML, through GHRH antagonism: MIA-602.

    Costoya J, et al.Reviews in endocrine & metabolic disorders2025PMID 39417961

    journal articlereview

  8. Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

    Thomas A, et al.Journal of mass spectrometry : JMS2024PMID 38197510

    journal article

  9. GHRH agonist MR-409 protects β-cells from streptozotocin-induced diabetes.

    Louzada RA, et al.Proceedings of the National Academy of Sciences of the United States of America2023PMID 37307472

    journal articleresearch support, non-u.s. gov'tresearch support, u.s. gov't, non-p.h.s.

  10. Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

    Cristea CD, et al.Analytical biochemistry2023PMID 37806509

    journal articleresearch support, non-u.s. gov't

  11. Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis.

    Otin J, et al.Electrophoresis2023PMID 36787346

    journal articleresearch support, non-u.s. gov't

  12. An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.

    Coppieters G, et al.Journal of pharmaceutical and biomedical analysis2022PMID 35298973

    journal article

  13. Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity.

    Cai R, et al.Peptides2022PMID 34952135

    journal articleresearch support, non-u.s. gov't

  14. Probing for peptidic drugs (2-10 kDa) in doping control blood samples.

    Thomas A, et al.Analytical science advances2022PMID 38716080

    journal article

  15. Advances in the detection of growth hormone releasing hormone synthetic analogs.

    Memdouh S, et al.Drug testing and analysis2021PMID 34665524

    journal articlevalidation study

  16. A glimpse at growth hormone-releasing hormone cosmos.

    Barabutis NClinical and experimental pharmacology & physiology2020PMID 32289177

    letterresearch support, n.i.h., extramuralresearch support, non-u.s. gov't

  17. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

    Sinha DK, et al.Translational andrology and urology2020PMID 32257855

    journal articlereview

  18. Glycine-modified growth hormone secretagogues identified in seized doping material.

    Gajda PM, et al.Drug testing and analysis2019PMID 30136411

    journal article

  19. Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis.

    Belavgeni A, et al.Proceedings of the National Academy of Sciences of the United States of America2019PMID 31611400

    journal articleresearch support, non-u.s. gov't

  20. Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin.

    Zhang C, et al.Lung2019PMID 31392398

    journal articleresearch support, u.s. gov't, non-p.h.s.

  21. Stimulatory effect of growth hormone-releasing hormone (GHRH(1-29)NH2) on the proliferation, VEGF and chromogranin A secretion by human neuroendocrine tumor cell line NCI-H727 in vitro.

    Stepień T, et al.Neuropeptides2009PMID 19747727

    journal articleresearch support, non-u.s. gov't

  22. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?

    Walker RFClinical interventions in aging2006PMID 18046908

    editorial

  23. Interactions of GRF(1-29)NH2 with plasma proteins and their effects on the release of the peptide from a PLAGA matrix.

    Mariette B, et al.Journal of controlled release : official journal of the Controlled Release Society2005PMID 15987661

    journal articleresearch support, non-u.s. gov't

  24. Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women.

    Khorram O, et al.The Journal of clinical endocrinology and metabolism1997PMID 9360512

    clinical trialjournal articlerandomized controlled trialresearch support, non-u.s. gov'tresearch support, u.s. gov't, p.h.s.

  25. VIP antagonist [N-Ac-Tyr1,D-Phe2]-GRF-(1-29)-NH2: an inhibitor of vasodilation in the feline colon.

    Blank MA, et al.The American journal of physiology1990PMID 2116730

    journal articleresearch support, non-u.s. gov't

  26. Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children.

    Brain CE, et al.Clinical endocrinology1990PMID 2140733

    journal article

Discussion

Sermorelin has its own forum, and sits in Testosterone & Hormones. Every post says what kind of claim it makes.

All threads
Personal anecdote0Cited research0Question0Discussion1

Membership

Peptides are free. The argument is for members.

The guide above is open to everyone, and the literature underneath it opens with a free account. That is the educational half of this site. Reading and joining the discussion around Sermorelin, and every other entry, is what membership pays for.

Unlock membershipSign in

From $3.33 a month, billed annually. Cancel anytime.

For Research & Educational Discussion Only. Not Medical Advice

This guide is educational reference material compiled from published literature. It is not medical advice, not a recommendation, and not a substitute for a clinician who knows your history. Nothing here should be used to make a decision about your own health without one.

Talk to a licensed healthcare professional.